SPO13 Antibody

What is SPO13 and why is it important to study with antibodies?

SPO13 is a key meiosis-specific regulator required for centromere cohesion and coorientation, and for progression through two nuclear divisions. It influences the activity of other kinases to prevent meiosis II events, such as loss of centromeric cohesion and spore formation . Studying SPO13 with antibodies is crucial because it helps researchers understand its role in cell cycle regulation, particularly during meiosis. SPO13 antibodies enable the detection, localization, and quantification of SPO13 proteins in various experimental systems, providing insights into its function and regulation during cell division processes.

What are the standard validation methods for SPO13 antibodies?

Standard validation for SPO13 antibodies, as with other antibodies, should include:

• Specificity testing through Western blot analysis

• Immunocytochemistry and immunohistochemistry validation

• Evaluation of immunoreactivity patterns

• Cross-reactivity testing

All antibodies should pass minimum criteria of standard antibody validation before being published or used in research . For internally produced antibodies (like those from the Human Protein Atlas), steps 1-4 of their standard validation process must be passed for use in immunohistochemistry and immunocytochemistry/IF applications, while steps 5-7 provide the basis for reliability scoring .

What experimental applications are suitable for SPO13 antibodies?

SPO13 antibodies can be utilized in multiple experimental applications:

• Western blotting to detect SPO13 protein levels during different cell cycle stages

• Immunofluorescence microscopy to visualize SPO13 localization, which can be primarily associated with the nucleolus

• Immunoprecipitation to identify SPO13 binding partners

• Chromatin immunoprecipitation (ChIP) to study DNA interactions if applicable

• Flow cytometry to quantify SPO13 in cell populations

When designing experiments, researchers should consider that SPO13 is phosphorylated and stabilized at G2/M in a Cdk/Clb-dependent manner, making cell cycle synchronization an important consideration .

How can I optimize detection of SPO13 during specific meiotic phases?

Optimizing SPO13 detection during specific meiotic phases requires careful experimental design:

• Cell synchronization: Use methods appropriate for your model system (e.g., nutrient deprivation in yeast)

• Time-course sampling: Collect samples at carefully timed intervals to capture different meiotic phases

• Co-staining: Use markers for meiotic progression (e.g., spindle morphology markers)

• Phosphorylation-specific antibodies: Consider using phospho-specific antibodies if studying SPO13 activation

Research shows that SPO13 expression and localization changes during meiosis, with evidence of nucleolar association early in arrest and multiple large nuclear foci at later timepoints . For optimal detection, fixation conditions should be optimized to preserve SPO13 epitopes while maintaining cellular architecture.

What controls should be included when performing epitope binning experiments with SPO13 antibodies?

When performing epitope binning experiments with SPO13 antibodies, include these essential controls:

• Positive control antibodies: Use validated antibodies targeting known epitopes of SPO13

• Negative control antibodies: Include irrelevant antibodies of the same isotype

• Blocking controls: Use purified SPO13 protein to demonstrate epitope-specific binding

• Cross-reactivity controls: Test against related proteins to ensure specificity

Epitope binning provides an efficient method for interrogating the epitope diversity of antibody panels . In a typical high-throughput SPR setup, you should include interspersed buffer blank analyte cycles for threshold settings and unmodified regions of the chip as interspot references . This approach enables the creation of competition matrices and network plots where antibodies are shown as nodes and their blocking relationships as chords, with envelopes inscribing node clusters defining the bins .

How does SPO13 overexpression affect cell cycle and how can this be measured using antibodies?

SPO13 overexpression affects the cell cycle in two distinct ways that can be measured using antibodies:

• G2/M arrest effects:

  • SPO13 causes a G2/M arrest that is reversible and largely independent of the Mad2 spindle checkpoint

  • It reduces mRNAs requiring Cdc14 activation, suggesting inhibition of Cdc14 function

  • The arrest correlates with Cdc14 phosphatase retention in the nucleolus and cyclin B accumulation

• Anaphase effects:

  • SPO13 delays anaphase progression, showing enrichment of anaphase spindles

  • It reduces Pds1 securin degradation, affecting cohesin cleavage

  • It inhibits cleavage of Scc1/Mcd1, which is important for chromosome segregation

To measure these effects, researchers can use antibodies against:

• SPO13 (to confirm expression)

• Pds1/securin (to assess degradation)

• Scc1/Mcd1 (to monitor cleavage)

• Cdc14 (to evaluate nucleolar release)

• Cyclin B/Clb2 (to assess accumulation)

A time-course experiment with synchronized cells and immunofluorescence or Western blot analysis can effectively measure these parameters.

What are common sources of non-specific binding with SPO13 antibodies and how can they be mitigated?

Common sources of non-specific binding with SPO13 antibodies include:

• Cross-reactivity with related proteins: SPO13 may share epitopes with other proteins

• Post-translational modifications: Modified forms of SPO13 may affect antibody recognition

• Fixation artifacts: Certain fixation methods may create artificial epitopes

• High antibody concentration: Excessive antibody can increase background

Mitigation strategies include:

• Optimized blocking: Use 5% BSA or 5% milk in TBS-T for Western blots

• Antibody titration: Determine the minimum effective concentration

• Validation with knockout/knockdown controls: Use spo13Δ samples as negative controls

• Pre-absorption: Pre-incubate antibody with recombinant SPO13 to confirm specificity

• Alternative fixation methods: Compare multiple fixation protocols to identify optimal conditions

How can I distinguish between SPO13's mitotic and meiotic roles when using antibodies in experimental systems?

Distinguishing between SPO13's mitotic and meiotic roles requires careful experimental design:

• Cell type selection: Use mitotic cells (with controlled SPO13 expression) versus meiotic cells

• Inducible expression systems: Employ systems like TET-SPO13 or GAL-SPO13 to control expression

• Co-localization studies: Use markers specific for mitotic or meiotic structures

• Functional readouts: Measure cell cycle-specific events such as:

  • Cohesin cleavage (Scc1/Mcd1 in mitosis versus Rec8 in meiosis)

  • Spindle morphology (metaphase versus anaphase spindles)

  • Cdc14 release from the nucleolus

Research shows that Spo13 regulates cohesin cleavage and when overexpressed in mitosis, it inhibits cleavage of Scc1/Mcd1 . The effects of SPO13 can be studied by monitoring the percentage of cells with metaphase or anaphase spindles along with Western blot analysis of proteins like Scc1, Cdc28, and Clb2 .

What is the recommended methodology for performing epitope mapping with SPO13 antibodies?

For epitope mapping with SPO13 antibodies, the following methodology is recommended:

• Peptide array analysis:

  • Synthesize overlapping peptides spanning the entire SPO13 sequence

  • Test antibody binding to identify reactive peptides

  • Narrow down to minimal epitope regions

• High-throughput epitope binning:

  • Immobilize SPO13 antibodies in an array format

  • Flow analytes (other antibodies) across the array

  • Analyze competition patterns to group antibodies into bins based on epitope

• Mutagenesis approach:

  • Create a library of SPO13 mutants with substitutions at key residues

  • Test antibody binding to identify critical residues for recognition

  • Confirm findings with point mutants

For high-throughput epitope binning, the experimental setup should include proper controls and reference surfaces as described in protocol examples that have successfully analyzed thousands of discrete pairwise interactions . The results can be visualized as network plots where antibodies are shown as nodes and their blocking relationships as chords, with envelopes inscribing node clusters defining the epitope bins .

How can proteomics data be integrated with SPO13 antibody studies to enhance research findings?

Integration of proteomics data with SPO13 antibody studies can significantly enhance research findings through:

• Complementary validation:

  • Use mass spectrometry to verify antibody specificity

  • Confirm antibody-detected changes in SPO13 levels or modifications with proteomic data

• Interaction network mapping:

  • Compare immunoprecipitation results with proteomics-identified interaction networks

  • Validate key interactions with targeted co-IP experiments

• Phosphorylation site analysis:

  • Use phosphoproteomics data to identify specific SPO13 phosphorylation sites

  • Develop phospho-specific antibodies for these sites

  • Correlate phosphorylation patterns with functional outcomes

• Temporal profiling:

  • Combine time-resolved proteomics with antibody-based time course experiments

  • Create integrated models of SPO13 regulation during cell cycle progression

Research has shown that proteome and phosphoproteome analysis of wild-type and spo13Δ cells can identify 3296 proteins and reveal crucial differences in key regulators like Pds1securin and Sgo1 . When integrating such data, researchers should focus on proteins that show altered abundance by more than 1.5-fold reliably between replicates .

What are the best practices for analyzing contradictory results between different SPO13 antibody-based experiments?

When analyzing contradictory results between different SPO13 antibody-based experiments:

• Validate antibody specificity:

  • Confirm each antibody recognizes SPO13 specifically

  • Test for cross-reactivity with related proteins

  • Verify recognition of relevant SPO13 species (phosphorylated vs. non-phosphorylated)

• Compare experimental conditions:

  • Examine differences in cell synchronization methods

  • Compare fixation and permeabilization procedures

  • Assess buffer compositions and blocking reagents

• Evaluate technical approaches:

  • Consider sensitivity differences between methods (Western blot vs. immunofluorescence)

  • Examine quantification methodologies

  • Assess dynamic range limitations

• Integrate multiple techniques:

  • Use orthogonal methods to verify findings

  • Combine antibody-based methods with genetic approaches (e.g., spo13Δ mutants)

  • Apply super-resolution microscopy to resolve localization discrepancies

When interpreting contradictory results, consider that SPO13 localization can change dynamically, with evidence showing it associates with the nucleolus early in arrest (where ~80% of SPO13-GFP foci colocalized with the nucleolar marker Nop1) but later forms multiple large nuclear foci that do not colocalize with either the mitotic spindle or the nucleolus .

How should researchers design experiments to study SPO13's role in regulating cohesin cleavage using antibodies?

To design experiments studying SPO13's role in regulating cohesin cleavage:

• Cell synchronization strategy:

  • Arrest cells at specific cell cycle stages (G1 with α-factor, metaphase with nocodazole)

  • Release from arrest and monitor progression

  • Use inducible systems like TET-SPO13 or GAL-SPO13 to control SPO13 expression

• Key proteins to monitor:

  • Scc1/Mcd1 (mitotic cohesin): Track cleavage products by Western blot

  • Rec8 (meiotic cohesin): Assess cleavage patterns in meiotic cells

  • Pds1/securin: Monitor degradation as a prerequisite for cohesin cleavage

  • Esp1/separase: Examine activity and localization

• Experimental setup:

  • Time-course sampling following synchronization

  • Parallel monitoring of spindle morphology by immunofluorescence

  • Western blot analysis of cohesin subunits and regulatory proteins

• Controls and variations:

  • spo13Δ mutant cells as comparison

  • TEV protease system to artificially cleave cohesin (e.g., SCC1-TEV268-HA constructs)

  • Esp1 overexpression to test suppression of SPO13 effects

Research has shown that SPO13 overexpression inhibits cleavage of Scc1/Mcd1, affecting cell cycle progression . Experimental designs should incorporate appropriate controls including Cdc28 as a loading control for Western blots and monitoring of both metaphase and anaphase spindles to track cell cycle progression .

How might emerging antibody technologies improve SPO13 research?

Emerging antibody technologies that could improve SPO13 research include:

• Single-domain antibodies (nanobodies):

  • Smaller size allows better penetration into cellular compartments

  • Can access epitopes that conventional antibodies cannot reach

  • Potential for live-cell imaging of SPO13 dynamics

• Proximity labeling with antibody-enzyme fusions:

  • SPO13 antibodies fused to enzymes like APEX2 or BioID

  • Allows identification of transient interaction partners

  • Can reveal spatial organization of SPO13 and associated proteins

• Bi-specific antibodies:

  • Simultaneous targeting of SPO13 and interacting partners

  • Enables detection of specific protein complexes

  • Can distinguish between different functional pools of SPO13

• Enhanced validation approaches:

  • CRISPR-based validation systems

  • Orthogonal binding reagents (aptamers, affimers)

  • AI-powered epitope prediction for improved antibody design

• Multiplexed detection systems:

  • Mass cytometry (CyTOF) for simultaneous detection of dozens of proteins

  • Imaging mass cytometry for spatial resolution of protein networks

  • Sequential imaging approaches for highly multiplexed detection

These technologies could help resolve outstanding questions about SPO13's dynamic localization, which has been observed to change from primarily nucleolar association to multiple large nuclear foci over time .

What are the key considerations for developing phospho-specific antibodies against SPO13?

Developing phospho-specific antibodies against SPO13 requires several key considerations:

• Phosphorylation site selection:

  • Identify functionally relevant phosphorylation sites using mass spectrometry

  • Focus on sites regulated during cell cycle progression

  • Prioritize conserved sites across species if applicable

• Peptide design:

  • Create phosphopeptides that include 10-15 amino acids surrounding the phosphorylation site

  • Ensure the phosphorylation site is centrally located in the peptide

  • Consider coupling to carrier proteins (KLH, BSA) for immunization

• Antibody production approach:

  • Monoclonal vs. polyclonal considerations

  • Species selection for immunization

  • Screening strategy to identify phospho-specific clones

• Validation requirements:

  • Test against phosphorylated and non-phosphorylated peptides

  • Validate with phosphatase-treated samples

  • Confirm with SPO13 phosphosite mutants (S→A or S→E mutations)

  • Test in spo13Δ backgrounds as negative controls

SPO13 is known to be phosphorylated and stabilized at G2/M in a Cdk/Clb-dependent manner , making phospho-specific antibodies particularly valuable for studying its regulation during cell cycle progression.